Centessa Pharmaceuticals (CNTA)
Centessa Pharmaceuticals Statistics
Share Statistics
Centessa Pharmaceuticals has 132.63M shares outstanding. The number of shares has increased by 32% in one year.
| Shares Outstanding | 132.63M |
| Shares Change (YoY) | 32% |
| Shares Change (QoQ) | 0.74% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 84.29M |
| Failed to Deliver (FTD) Shares | 886 |
| FTD / Avg. Volume | 0.09% |
Short Selling Information
The latest short interest is 5.2M, so 3.9% of the outstanding shares have been sold short.
| Short Interest | 5.2M |
| Short % of Shares Out | 3.9% |
| Short % of Float | 4.61% |
| Short Ratio (days to cover) | 4.11 |
Valuation Ratios
The PE ratio is -8.13 and the forward PE ratio is -8.32. Centessa Pharmaceuticals's PEG ratio is -0.26.
| PE Ratio | -8.13 |
| Forward PE | -8.32 |
| PS Ratio | 0 |
| Forward PS | 3.8 |
| PB Ratio | 4.78 |
| P/FCF Ratio | -13.49 |
| PEG Ratio | -0.26 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Centessa Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.25, with a Debt / Equity ratio of 0.29.
| Current Ratio | 9.25 |
| Quick Ratio | 9.25 |
| Debt / Equity | 0.29 |
| Debt / EBITDA | -0.58 |
| Debt / FCF | -0.83 |
| Interest Coverage | 19.94 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-3.06M |
| Employee Count | 77 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 2.84M |
| Effective Tax Rate | -1.22% |
Stock Price Statistics
The stock price has increased by 44.83% in the last 52 weeks. The beta is 1.54, so Centessa Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 1.54 |
| 52-Week Price Change | 44.83% |
| 50-Day Moving Average | 14.55 |
| 200-Day Moving Average | 15.03 |
| Relative Strength Index (RSI) | 52.87 |
| Average Volume (20 Days) | 1.02M |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -201.06M |
| Net Income | -235.76M |
| EBITDA | -201.06M |
| EBIT | -243M |
| Earnings Per Share (EPS) | -2.06 |
Balance Sheet
The company has 383.22M in cash and 117.23M in debt, giving a net cash position of 266M.
| Cash & Cash Equivalents | 383.22M |
| Total Debt | 117.23M |
| Net Cash | 266M |
| Retained Earnings | -988.7M |
| Total Assets | 576.8M |
| Working Capital | 478.41M |
Cash Flow
In the last 12 months, operating cash flow was -142.06M and capital expenditures -34K, giving a free cash flow of -142.09M.
| Operating Cash Flow | -142.06M |
| Capital Expenditures | -34K |
| Free Cash Flow | -142.09M |
| FCF Per Share | -1.24 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CNTA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CNTA is $28, which is 103.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $28 |
| Price Target Difference | 103.9% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Scores
| Altman Z-Score | 3.58 |
| Piotroski F-Score | 2 |